Other Bullards

by Edgar John Bullard

1928

This is supplement #1 to work entitled: Bullard and allied families : the American ancestors of George Newton Bullard and Mary Elizabeth Bullard / by Edgar J. Bullard. Detroit, Mich. : E.J. Bullard, 1930. "Many records of Bullard families were received in the extensive correspondence pursued in the quest of John Bullard's descendants (Bullard and allied families by E.J. Bullard). These records seemed too valuable to discard and it was thought best to place them in a separate volume. No effort has bewen made to verify them or connect them, excepting those that naturally could be grouped in the families of William, Robert, and George Bullard (brothers of John Bullard), Thomas and Reuben Bullard of Virginia, and a few southern families that are not connected as far as ascertainable. The rest are left as unclassified and are arranged alphabetically." (p. 3).

The History of Peter Parker and Sarah Ruggles of Roxbury, Mass. and Their Ancestors and Descendants, with the Best Wishes of the Author

by John William Linzee

1918

Peter Parker (1720-1765) married Sarah Ruggles in 1752/1753, and lived in Roxbury and Brookline, Massachusetts. Descendants and relatives lived in New England, New York, Maryland, Missouri, Wisconsin, California and elsewhere. Includes many ancestors and some descendants of these ancestors, living in England, India and elsewhere.

The Emergence of Drugs which Block Calcium Entry

by Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly

2013 · Springer Science & Business Media

Calcium Entry Blockers (CEBs) are a new class of drugs which have been pushing back the frontiers of science and medicine for almost two decades. This report reviews some of the wealth of chemical, biological and clinical data describing the discovery and development of these compounds. The scientific importance, therapeutic benefit and marketing potential of these compounds have caused an explosion of scientific literature describing their effects in many preclinical and clinical settings. The definitional characteristics of these compounds suggest a certain predictability of their biological profile but their therapeutic usefulness varies widely dependent upon their physical properties, net hemodynamic effects, duration of action and incidence of side effects. CEBs appear uniquely suited to the treatment of the underlying complexity of cardiovascular disease. The CEBs of the future may live up to the expectations of pathophysiologically based therapeutics and allow the heart and blood vessels to outlive the cells which they support. The development of CEBs is an evolving story of epic proportions and represents the cooperative efforts of individuals in all areas of science.